Oncology Clinical Trials at UT Veterinary Medical Center
(November 26, 2013 Knoxville, TN)
The Oncology Service at the University of Tennessee Veterinary Medical Center (UTVMC) is currently conducting clinical trials recruiting the following tumor types:
Dogs- high grade lymphoma, multiple myeloma, histiocytic sarcoma (malignant histiocytosis), mast cell tumors, transitional cell carcinoma (bladder), colorectal tumors, oral squamous cell carcinoma.
Cats- oral squamous cell carcinoma, colorectal tumors, transitional cell carcinoma, non-resectable sarcomas and carcinomas. A new trial is coming in December for feline high grade lymphoma!
1. Tumor type: Canine B cell lymphoma. Trial: Evaluation of oncolytic viruses in canine cancer. (Partnership with the Mayo Clinic.)
The goal of this trial is to evaluate the response of lymphoma to an oncolytic virus designed to infect cancer cells but not normal cells. This trial is fully funded. Patients ideally should be off other therapies (including steroids) for 2 weeks prior to enrollment. The trial period is for 30 days and you must be able to travel to UTVMC in Knoxville once a week for 4 visits. Other tumor types may be considered, please have your veterinarian call (865) 974-8387.
2. Tumor type: Oral (mouth/head & neck) tumors in both dogs and cats, bladder tumors, and colorectal tumors. Trial: Evaluating a novel optical imaging agent, fluorocoxib A, to detect cyclooxygenase-2 (COX-2) expressing cancers of bladder, head and neck, breast, colon or ovary in dogs and cats.
This study uses a new optical imaging agent to target receptors in certain tumor types. The trial period is 24 hours, is fully funded, and will cover the cost of a biopsy in oral tumors and in bladder tumors for diagnosis. Patients must be off non-steroid anti-inflammatory drugs for 2 weeks before enrollment or biopsy.
3. Tumor type: Canine histiocytic sarcoma. Trial: Phase II, Open Label Trial of Paccal Vet (water-soluble micellar paclitaxel) in Dogs with Histiocytic Sarcoma. (Partnership with Oasmia Pharmaceuticals)
This trial will evaluate a new canine chemotherapy agent for histiocytic sarcoma in dogs. This trial includes financial incentives to the client: treatment drug provided at no cost and staging tests are covered to determine response to drug after 6 weeks of treatment. Trial period is 6 weeks (7 total veterinary visits required- 4 can be done with your local veterinarian, 3 must be at UTVMC). If your dog responds to treatment, the study will provide additional drug for continued treatment after the 6 week enrollment period. Dogs should be off other chemotherapy and steroids for 2 weeks prior to enrollment.
4. Tumor type: Canine mast cell tumors (skin tumor). Trial: Use of Kinavet (masitinib) for non-resectable canine mast cell tumors.
This trial evaluates Kinavet in dogs with non-surgical mast cell tumors. The trial is fully funded. Kinavet is under conditional FDA licensure for the treatment of mast cell tumors in dogs. This is a placebo-controlled trial, thus 2/3 of the dogs will receive the study drug and 1/3 will receive placebo. To qualify, dogs cannot be on chemotherapy and should be off steroids for at least 3 weeks. A screening visit at UTVMC is required to determine eligibility.
5. Tumor type: Canine transitional cell carcinoma (bladder cancer). Trial: Pilot study, Neurotransmitter levels in blood samples of dogs with and without transitional cell carcinoma.
Research by Dr. Hildegard Schuller's lab has shown that high blood levels of cancer-stimulating stress chemicals can stimulate certain cancer types. This study will determine if dogs with bladder cancer (transitional cell carcinoma) have increased stress chemical levels and/or decreased GABA levels. Patients must be untreated (NSAIDs are not allowed). Patients can present to UTVMC or referring veterinarians may submit blood for use in this study. A single 5mL (teaspoon) blood sample is needed for study. There is no cost to client for participation.
Please note: For all trials, clients are responsible for the initial examination fee for the first visit (currently $127) and any test required to determine eligibility (many trials require some staging tests performed to determine eligibility). Each trial has different funding and an explanation of covered costs and non-covered costs will be reviewed with each case. To have your pet evaluated for possible candidacy in a trial, please contact your primary care veterinarian and discuss your pet's candidacy or request a referral to UTVMC.
Posted: 11-26-13 Viewed: 16866 times
Media RelationsSandra Harbison
College of Veterinary Medicine
University of Tennessee
2407 River Drive
Knoxville, TN 37996